Get the Stockscreener App
47.13
0.55%
-0.26
Qiagen Nv stock is traded at $47.13, with a volume of 367.37K.
It is down -0.55% in the last 24 hours and up +11.92% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
See More
Previous Close:
$47.39
Open:
$46.645
24h Volume:
367.37K
Relative Volume:
0.27
Market Cap:
$9.87B
Revenue:
$1.98B
Net Income/Loss:
$83.59M
P/E Ratio:
126.02
EPS:
0.374
Net Cash Flow:
$502.31M
1W Performance:
+3.63%
1M Performance:
+11.92%
6M Performance:
+0.93%
1Y Performance:
+5.70%
1-Day Range:
$46.60
$47.19
1-Week Range:
$45.59
$47.40
52-Week Range:
$37.74
$49.30
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
47.15 | 9.87B | 1.98B | 83.59M | 502.31M | 0.374 |
|
TMO
Thermo Fisher Scientific Inc
|
409.62 | 150.38B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
203.05 | 137.52B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
523.52 | 42.00B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
118.61 | 32.37B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
158.69 | 25.50B | 15.50B | 1.33B | 2.16B | 7.34 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
Qiagen Announces Significant Shareholding Notification - TipRanks
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Molecular Diagnostics for Cancer Market Research 2025: Advances in Personalized Medicine and Liquid Biopsies Reshape Industry Landscape - GlobeNewswire Inc.
Qiagen Announces Voting Rights Notification by AFM - TipRanks
Here's Why Qiagen (QGEN) is a Strong Momentum Stock - Yahoo Finance
QIAGEN expands portfolio for MRD testing in oncology with two partnerships - MSN
Qiagen (NYSE:QGEN) Receives Average Rating of “Hold” from Brokerages - Defense World
QIAGEN (QGEN) Partners with Tracer Biotechnologies for MRD Assays - GuruFocus
Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
QGEN Partners with Tracer Biotechnologies to Advance Cancer Test - GuruFocus
Qiagen (NYSE:QGEN) Sees Large Increase in Short Interest - Defense World
Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors - marketscreener.com
Qiagen N.V. (QGEN) Expands MRD Testing with Tracer and Foresight Partnerships - MSN
QGEN Partners with Tracer Biotechnologies to Advance Cancer Testing | QGEN Stock News - GuruFocus
Qiagen, Tracer Biotechnologies announce strategic partnership - TipRanks
Transcript : Qiagen N.V. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 09 - marketscreener.com
Qiagen N.V. Reports Significant Voting Rights Held by BlackRock - TipRanks
Forensic Genomics Market Research 2025Global Trends, Opportunity, and Forecasts 2020-2030 - GlobeNewswire Inc.
Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term - Yahoo Finance
Here's Why Qiagen (QGEN) is a Strong Value Stock - Yahoo Finance
QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances - Yahoo Finance
QIAGEN NV : Receives a Buy rating from Deutsche Bank - marketscreener.com
Qiagen expands portfolio for minimal residual disease testing in oncology - BioSpectrum Asia
Foresight Diagnostics and Qiagen Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma - marketscreener.com
Qiagen Enters Partnerships, Expands Portfolio for Minimal Residual Disease Testing in Oncology - marketscreener.com
QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships - Business Wire
Foresight Diagnostics And Qiagen Announce Strategic Partnership To Advance Development Of Companion Diagnostic Kits For Lymphoma - marketscreener.com
Qiagen (QGEN) Forms Strategic Alliance with Foresight Diagnostic - GuruFocus
Qiagen (QGEN) Forms Strategic Alliance with Foresight Diagnostics | QGEN Stock News - GuruFocus
Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma - marketscreener.com
Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma – Company AnnouncementFT.com - Financial Times
Equities Analysts Set Expectations for Qiagen Q2 Earnings - Defense World
Ameriprise Financial Inc. Grows Stake in Qiagen (NYSE:QGEN) - Defense World
QIAGEN NV : Berenberg gives a Buy rating - marketscreener.com
Cetera Investment Advisers Acquires 1,418 Shares of Qiagen (NYSE:QGEN) - Defense World
Qiagen NV (QGEN) Trading 4% Higher on May 27 - GuruFocus
QIAGEN NV : Receives a Buy rating from DZ Bank - marketscreener.com
Cell-Free DNA Isolation and Extraction Market - GlobeNewswire Inc.
Europe Digital PCR Industry Research Report 2025: Increased Use of Digital-PCR-Based Solutions for the Development of Therapeutics Drugs and Comprehensive Treatment Plans - GlobeNewswire Inc.
Qiagen and ID Solutions Partner to Enhance Digital PCR Assays for Oncology Research - Insider Monkey
QIAGEN expands digital PCR oncology research portfolio through p - GuruFocus
QGEN Stock Might Gain Following New Partnership With ID Solutions - TradingView
Qiagen and ID Solutions collaborate on dPCR assays for oncology research - Medical Device Network
QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions - Silicon Canals
QIAGEN (QGEN) Expands dPCR Assay Availability Through New Partnership | QGEN Stock News - GuruFocus
QIAGEN acquires AI-powered software, Genoox - MSN
Qiagen Receives Notification of BlackRock’s Voting Rights - TipRanks
QIAGEN Stock Gains Following the Acquisition of Genoox - MSN
Qiagen Stock Beats Earnings, But Its Expensive Valuation Caps Upside Potential (NYSE:QGEN) - Seeking Alpha
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):